How low can an anti-doping test see, and for how long after administration does that reach still catch the drug?
Before an anti-doping laboratory can say a sample is "clean," it must first define precisely what "clean" means analytically. Every quantitative bioanalytical method has three interlocking sensitivity benchmarks — the Limit of Detection (LOD), the Limit of Quantitation (LOQ), and the regulatory Minimum Required Performance Level (MRPL) that WADA mandates for each prohibited substance. These are not abstract numbers: they define the boundary between a sanctioned career-ending positive and an undetected doping violation.
The Limit of Detection and Limit of Quantitation answer two distinct questions, and confusing them is a common analytical error:
Limit of Detection (LOD): • "Is the analyte present at all, distinguishable from a blank matrix?" • Typically defined as the concentration producing a peak with signal-to-noise ratio ≈3:1 • Statistically: mean blank response + 3×standard deviation of blank replicates • Below LOD: analyst cannot state with confidence that the substance is present — reported as "not detected"
Limit of Quantitation (LOQ): • "At what concentration can I report a reliable numeric value, not just presence/absence?" • Typically S/N ≈10:1, or LOD × 3–3.3 in practice • Requires acceptable precision (CV <20%) and accuracy (80–120% of nominal) across replicate injections • Between LOD and LOQ: substance is detected but not reliably quantified — a qualitative "presence" call only
WADA's anti-doping rule violations are usually built on a qualitative identification (retention time match + at least 3 diagnostic ion transitions in LC-MS/MS matching a reference standard within tolerance), so many adverse analytical findings are reported at or even below classical LOQ, provided identification criteria are unambiguous — the LOD, not the LOQ, is functionally the deciding threshold for most doping cases.
WADA does not simply trust each laboratory to be "sensitive enough" — it publishes a Technical Document (TD2021MRPL and successors) specifying, substance by substance, the minimum concentration every accredited laboratory must be able to reliably detect. This harmonizes global testing: an athlete cannot exploit a less sensitive lab in one jurisdiction.
Representative MRPL examples (urine, approximate, illustrative of order of magnitude): • Anabolic androgenic steroids (most metabolites): 0.2–2 ng/mL • Stimulants (amphetamine-class): 100–500 ng/mL (higher MRPL — these are acute-use, high-dose stimulants) • Diuretics/masking agents: 20–200 ng/mL • Peptide hormones (hGH-releasing peptides): low ng/mL to sub-ng/mL • Erythropoiesis-stimulating agents (rEPO family): resolved by isoelectric focusing band pattern, not a simple concentration MRPL
Laboratories must demonstrate, through proficiency testing and method validation, that their LOD sits comfortably below the published MRPL — typically with a safety margin so that normal day-to-day instrument drift never pushes effective sensitivity above the regulatory floor.
MRPLs are revised almost every year as mass spectrometry hardware improves. A substance with an MRPL of 5 ng/mL in 2010 might carry an MRPL of 0.5 ng/mL by 2024 — a tenfold sensitivity gain that alone can convert thousands of archived "negative" samples into candidates for retroactive re-analysis.
A raw urine or blood sample is a dense chemical soup of salts, proteins, pigments, and thousands of endogenous metabolites — injecting it directly into a mass spectrometer would foul the instrument and swamp the analyte signal. Sample preparation strips this complexity down to a clean extract enriched in the target analyte, but every extraction step has an efficiency less than 100%, and every step that fails to fully remove co-eluting matrix components can suppress or enhance the very signal the assay depends on.
A typical anti-doping urine workup proceeds through several stages before the sample ever reaches the mass spectrometer:
1. Enzymatic hydrolysis: most steroid metabolites are excreted as glucuronide or sulfate conjugates. β-glucuronidase (often from E. coli or Helix pomatia) cleaves the sugar group, liberating the free steroid for extraction — incomplete hydrolysis directly lowers apparent concentration and can push a true positive below LOD.
2. Liquid-liquid extraction (LLE) or solid-phase extraction (SPE): the sample is passed through a sorbent cartridge (C18, mixed-mode cation/anion exchange) that selectively retains the analyte class while polar salts and proteins wash through. Elution with an organic solvent yields a concentrated, purified extract.
3. Evaporation and reconstitution: the extract is dried under nitrogen and reconstituted in a small volume of mobile phase — this concentration step is what allows detection of analytes present at only picograms per milliliter in the original sample.
4. Derivatization (for GC-MS workflows): some steroids are chemically derivatized (e.g., trimethylsilylation) to improve volatility and mass spectral fragmentation before gas chromatography.
Recovery efficiency — the fraction of analyte that survives this entire process — is validated during method development, typically 70–95% for well-optimized SPE protocols. A method with only 50% recovery effectively doubles its practical LOD relative to the same instrument's raw capability.
Even after extraction, co-eluting endogenous compounds (phospholipids, salts, other metabolites sharing similar retention time) can interfere with the electrospray ionization process itself:
Ion suppression: competing analytes reduce the efficiency of droplet formation and gas-phase ion transfer, lowering the observed signal for the target analyte even though it is genuinely present — this can make a sample falsely appear to be below LOD.
Ion enhancement: less common, but co-eluting compounds can occasionally increase ionization efficiency, giving falsely elevated readings.
Mitigation strategies used in accredited labs: • Stable isotope-labeled internal standards (deuterated or ¹³C-labeled analogues) added before extraction — they experience identical suppression/enhancement, allowing normalization of the true analyte signal • Chromatographic optimization to separate the analyte from major suppressing co-eluents • Post-column infusion experiments during method validation to map suppression zones across the chromatogram and ensure the analyte does not elute within a suppression valley • Dilute-and-shoot approaches for high-concentration classes (some stimulants) to minimize matrix load, trading some sensitivity for cleaner ionization
Because matrix effects are sample-specific (a dehydrated athlete's concentrated urine behaves differently from a well-hydrated one), lab protocols also normalize reported concentrations against urine specific gravity, and abnormally concentrated or dilute samples can trigger separate reporting flags.
Even a perfectly designed, perfectly executed assay is only useful for as long as the drug (or its detectable metabolites) remains above the instrument's LOD in the athlete's system. Concentration after administration follows an approximately exponential decline governed by the substance's elimination half-life — and the detection window is simply the stretch of time during which that decay curve sits above the horizontal LOD line. Lower the LOD, and the window stretches; raise it, and the window shrinks, sometimes to nothing.
Most xenobiotics (foreign substances) follow approximate first-order elimination kinetics once absorption and distribution have equilibrated:
C(t) = C₀ · e^(−k·t), where k = ln(2) / t½
C₀ = peak concentration shortly after administration, t½ = elimination half-life, k = elimination rate constant.
The detection window is the time interval [0, t_LOD] during which C(t) remains above the assay LOD:
t_LOD = (1/k) · ln(C₀ / LOD) = (t½ / ln2) · ln(C₀ / LOD)
This single equation captures the entire arms race of anti-doping science: t_LOD grows only logarithmically with improvements in C₀/LOD ratio, but linearly with the substance's half-life. A ten-fold improvement in LOD (say 200 pg/mL → 20 pg/mL) only extends the detection window by (t½/ln2)·ln(10) ≈ 3.3 half-lives worth of extra time — meaningful, but not unlimited. This is why combining a lower LOD with knowledge of long-lived metabolites (rather than the fast-cleared parent drug) is the most powerful lever available to detection science.
Fast-clearing substances (many stimulants, short-ester testosterone esters) may have windows of only hours to 1–2 days; slow-clearing substances (long-ester anabolic steroids, some designer steroids with lipophilic depots) can remain detectable for weeks to months, which is precisely why long-ester "designer" steroids were historically favored by dopers seeking a shorter window, then countered by labs identifying long-lived unique metabolites.
Human growth hormone (hGH) and recombinant erythropoietin (rEPO) are textbook examples of substances whose natural detection windows are brutally short, driving the entire anti-doping field toward indirect biomarker strategies:
hGH — dual testing strategy: • Isoform differential immunoassay: recombinant hGH is a single 22kDa isoform, while pituitary-derived natural hGH is a mixture of isoforms (22kDa, 20kDa, and fragments). Exogenous rhGH skews the isoform ratio detectably — but only for about 12–24 hours post-injection, since the body's own isoform mix re-equilibrates quickly. • Biomarkers test: measures downstream effects — IGF-I and P-III-NP (procollagen III N-terminal propeptide) — which rise and stay elevated for longer, extending the practical window to roughly 24–36 hours, at the cost of being an indirect (not direct-detection) method requiring population-based decision limits rather than a simple LOD.
rEPO — isoelectric focusing (IEF): • Rather than a concentration-based LOD, EPO doping is detected by the isoelectric focusing banding pattern: recombinant EPO glycoforms migrate to different positions than endogenous EPO, producing a visually and densitometrically distinguishable band pattern. • Detection window in urine is short — commonly cited as roughly 2–4 days after the last microdose, because rEPO is cleared quickly and endogenous EPO production resumes, diluting the distinguishing band signature. • This narrow window motivated athlete biological passport monitoring of blood parameters (reticulocyte percentage, OFF-score) as a longitudinal indirect complement to the short direct-detection window.
Textbook diagrams draw the LOD as a hard line: above it, detected; below it, invisible. Real assays behave more like a sigmoid — a smooth S-curve of detection probability that only approaches (never instantly reaches) 100% as concentration rises well above LOD, and only approaches 0% well below it. In the narrow band straddling the threshold, results are probabilistic, and this statistical soft edge is exactly the zone that microdosing protocols are designed to exploit.
The LOD is a statistical construct derived from the distribution of blank and low-concentration replicate measurements, not a physical wall. Instrument noise, extraction variability, and day-to-day chromatographic drift all contribute a spread of possible signal readings for any true underlying concentration.
A convenient working model: P(detect | C) = 1 / (1 + e^(−(C−LOD)/w))
where w is a "transition width" parameter reflecting the assay's measurement noise (a sharper, more precise assay has smaller w and a steeper, more step-like sigmoid; a noisier assay has larger w and a more gradual ramp).
At C = LOD exactly, P(detect) ≈ 50% by the very construction of most LOD definitions — meaning a sample sitting precisely at the nominal LOD is, in effect, a coin flip. Confident calls in either direction require concentration to sit well clear of the threshold: roughly 3× LOD for a confident positive, well below 0.5× LOD for a confident negative.
This has a direct and unavoidable consequence: any doping protocol that keeps the analyte's peak concentration hovering just above LOD, rather than far above it, converts what should be a certain detection into a probabilistic one — and probabilistic detection, repeated across many test occasions, still eventually catches most violators, but individual test occasions can and do produce false negatives.
Micro-dosing protocols deliberately administer small, frequent doses (often 5–20% of a standard therapeutic or performance dose) rather than a single large dose. The strategic logic directly targets assay sensitivity limits:
• Lower peak concentration (C₀): smaller doses never push C(t) far above LOD, keeping the athlete in the probabilistic detection zone rather than the confident-positive zone for most or all of the dosing interval • Shorter time above LOD: even though total drug exposure over a training cycle may be substantial, each individual dose's excursion above threshold is brief — sometimes only a few hours — narrowing the window during which an unannounced test would catch it • Timing around test predictability: combined with knowledge of competition testing schedules and (in the worst historical cases) advance notice of "no-notice" tests, doses are scheduled so concentration has already decayed back toward baseline by the time sample collection is likely • Transdermal, oral micro-formulations, and pulsed regimens: designed to produce these short, low peaks by pharmacokinetic design rather than accident
Counter-strategies developed by anti-doping authorities directly attack each of these levers: intelligence-led, unpredictable out-of-competition testing collapses the "predictable timing" advantage; longitudinal athlete biological passport monitoring detects the physiological footprint of repeated microdosing even when no single sample shows a direct positive; and continually falling assay LOD values shrink the probabilistic gray zone that microdosing is designed to live inside, forcing ever-smaller and less physiologically effective doses to stay hidden.
Because P(detect) never truly reaches exactly 0% or exactly 100%, no finite testing protocol offers perfect certainty in either direction. This is precisely why anti-doping systems layer multiple independent methods — direct chemical detection, longitudinal biomarker passports, and long-term sample storage for future re-analysis — rather than relying on any single assay's LOD as the sole line of defense.
Anti-doping science does not stop the day a sample is tested. WADA rules require accredited laboratories and major event organizers to store B-samples (and often A-sample residuals) for up to ten years, explicitly anticipating that analytical sensitivity will keep improving. A sample that returns a clean result today, with today's LOD, can be pulled from a freezer years later and re-analyzed with an assay ten or a hundred times more sensitive — turning yesterday's false negative into today's confirmed, sanctionable positive.
Long-term sample storage converts anti-doping from a purely reactive, point-in-time test into an ongoing deterrent that never fully expires within its storage window. The logic works on two fronts simultaneously:
1. Direct re-analysis with improved assays: as LC-MS/MS instruments, extraction chemistries, and reference standard libraries improve, laboratories periodically re-screen banked samples from major championships against updated method panels — including for substances that were not even known or testable at the time of original collection (new designer steroids, newly characterized EPO analogues, newly developed peptide hormone assays).
2. Psychological deterrence: because an athlete cannot know in advance which future analytical breakthroughs will be applied retroactively to their stored samples, the mere existence of a 10-year re-testing window discourages doping strategies that rely on "getting away with it" at the moment of testing, since that moment is not actually final.
High-profile re-analysis campaigns from the Beijing 2008 and London 2012 Olympic Games identified dozens of additional adverse findings years after the original competitions, using improved detection methods for anabolic steroids and other substances that had been effectively invisible to the original-era assays — resulting in medal reallocations years after the events concluded.
Assay sensitivity is not a static engineering constant — it is on a continual improvement trajectory driven by instrument hardware (triple-quadrupole and high-resolution Orbitrap/Q-TOF mass spectrometers), better sample cleanup chemistries, and more sophisticated data processing (isotope-ratio mass spectrometry to distinguish endogenous from exogenous steroids of identical molecular structure).
Illustrative sensitivity trajectories:
• Anabolic steroid metabolites: LC-MS/MS MRPLs for many nandrolone and testosterone-class metabolites fell roughly an order of magnitude between the early 2000s and the 2020s as triple-quadrupole instruments replaced older GC-MS-only workflows and matured.
• Growth hormone isoform assay: originally validated with a relatively short post-injection window; refinements to decision limits, reference population studies, and paired biomarker/isoform testing extended practical detection confidence without necessarily needing lower LOD per se — a reminder that "improving sensitivity" includes statistical and study-design gains, not only raw instrument LOD.
• EPO detection: transition from urinary isoelectric focusing alone toward combined blood-based and urine-based methods, plus athlete biological passport longitudinal profiling, effectively extended the practical detection window well beyond the short direct-chemical window by adding an entirely independent, longer-lived detection axis (physiological adaptation rather than drug concentration).
• Long-term storage plus new analyte panels: some designer steroids and peptides not even chemically characterized at the time of original sample collection were later identified, synthesized as reference standards, and specifically searched for in archived samples — a pathway to positives that did not exist as an analytical possibility at the time of the original competition.
The combination of long-term storage and continuously falling MRPLs means that the true "detection window" for a sophisticated doping program is not simply the pharmacokinetic decay window computed at today's LOD — it is that window, plus the entire span of the storage period during which tomorrow's more sensitive assay might still catch what today's assay missed. In this sense, anti-doping sensitivity is not a fixed threshold but a moving target that only ever moves in the athlete's disfavor.